199 related articles for article (PubMed ID: 31341646)
1. Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α.
Qiu Y; Shan W; Yang Y; Jin M; Dai Y; Yang H; Jiao R; Xia Y; Liu Q; Ju L; Huang G; Zhang J; Yang L; Li L; Li Y
Cell Death Discov; 2019; 5():120. PubMed ID: 31341646
[TBL] [Abstract][Full Text] [Related]
2. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
4. PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells.
Long Q; Zou X; Song Y; Duan Z; Liu L
Biochem Biophys Res Commun; 2019 Jun; 513(3):642-650. PubMed ID: 30981500
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Liu LP; Ho RL; Chen GG; Lai PB
Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
7. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3η/NF-κB feedback loop.
Qiu Y; Dai Y; Zhang C; Yang Y; Jin M; Shan W; Shen J; Lu M; Tang Z; Ju L; Wang Y; Jiao R; Xia Y; Huang G; Yang L; Li Y; Zhang J; Wong VKW; Jiang Z
J Exp Clin Cancer Res; 2018 Dec; 37(1):321. PubMed ID: 30572915
[TBL] [Abstract][Full Text] [Related]
9. Iron deficiency in hepatocellular carcinoma cells induced sorafenib resistance by upregulating HIF-1α to inhibit apoptosis.
Gao Z; Wang D; Yang J; Li M; Ling C; Lv D; Cao Y; Chen Z; Shi C; Shen H; Tang Y
Biomed Pharmacother; 2023 Jul; 163():114750. PubMed ID: 37087978
[TBL] [Abstract][Full Text] [Related]
10. Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma.
Zeng Z; Lu Q; Liu Y; Zhao J; Zhang Q; Hu L; Shi Z; Tu Y; Xiao Z; Xu Q; Huang D
Front Oncol; 2021; 11():641522. PubMed ID: 34307125
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.
Méndez-Blanco C; Fondevila F; García-Palomo A; González-Gallego J; Mauriz JL
Exp Mol Med; 2018 Oct; 50(10):1-9. PubMed ID: 30315182
[TBL] [Abstract][Full Text] [Related]
12. 14-3-3η is a novel growth-promoting and angiogenic factor in hepatocellular carcinoma.
Shen J; Jiang F; Yang Y; Huang G; Pu F; Liu Q; Chen L; Ju L; Lu M; Zhou F; Zhang C; Luo X; Yang X; Jiao C; Li X; Li Z; Li Y; Zhang J
J Hepatol; 2016 Nov; 65(5):953-962. PubMed ID: 27210426
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor-1α: A critical target for inhibiting the metastasis of hepatocellular carcinoma.
Chen H; Chen J; Yuan H; Li X; Li W
Oncol Lett; 2022 Aug; 24(2):284. PubMed ID: 35814827
[TBL] [Abstract][Full Text] [Related]
14. MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma.
Bergamini C; Leoni I; Rizzardi N; Melli M; Galvani G; Coada CA; Giovannini C; Monti E; Liparulo I; Valenti F; Ferracin M; Ravaioli M; Cescon M; Vasuri F; Piscaglia F; Negrini M; Stefanelli C; Fato R; Gramantieri L; Fornari F
J Exp Clin Cancer Res; 2023 Jun; 42(1):145. PubMed ID: 37301960
[TBL] [Abstract][Full Text] [Related]
15. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
Bort A; Sánchez BG; Mateos-Gómez PA; Vara-Ciruelos D; Rodríguez-Henche N; Díaz-Laviada I
Mol Oncol; 2019 May; 13(5):1311-1331. PubMed ID: 30959553
[TBL] [Abstract][Full Text] [Related]
16. UBE2S promotes malignant properties via VHL/HIF-1α and VHL/JAK2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma.
Wu J; Xu X; Wu S; Shi W; Zhang G; Cao Y; Wang Z; Wu J; Jiang C
Cancer Med; 2023 Sep; 12(17):18078-18097. PubMed ID: 37563971
[TBL] [Abstract][Full Text] [Related]
17. Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis.
Wu H; Wang T; Liu Y; Li X; Xu S; Wu C; Zou H; Cao M; Jin G; Lang J; Wang B; Liu B; Luo X; Xu C
J Exp Clin Cancer Res; 2020 Dec; 39(1):274. PubMed ID: 33280610
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.
Li TT; Mou J; Pan YJ; Huo FC; Du WQ; Liang J; Wang Y; Zhang LS; Pei DS
J Biomed Sci; 2021 Aug; 28(1):56. PubMed ID: 34340705
[TBL] [Abstract][Full Text] [Related]
19. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
[TBL] [Abstract][Full Text] [Related]
20. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
Song Z; Liu T; Chen J; Ge C; Zhao F; Zhu M; Chen T; Cui Y; Tian H; Yao M; Li J; Li H
Cancer Lett; 2019 Sep; 460():96-107. PubMed ID: 31247273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
